+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
ID07008716

Reducing Target Area in Radiation for Limited-Stage Small Cell Lung Cancer A Randomized Study Comparing Standard and Reduced Radiotherapy Approaches

Led by Sun Yat-sen University · Updated on 2025-06-06

852

Participants Needed

2

Research Sites

261 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new approach to radiotherapy for patients with limited-stage small cell lung cancer LS-SCLC. This randomized controlled trial compares standard radiotherapy that includes the clinical target volume CTV for the primary tumor with a treatment that omits the CTV. The goal is to see if reducing the target volume can maintain cancer control while lowering radiation exposure to healthy organs and reducing side effects. Participants receive chemotherapy with either etoposide combined with carboplatin or cisplatin for 4 to 6 cycles. After 2 to 4 cycles, they undergo thoracic radiotherapy, given either twice daily or once daily, depending on the group. The control group receives radiotherapy including a 0.8 cm margin around the tumor CTV, while the experimental group omits this margin. Patients who respond to treatment without brain metastasis may then receive prophylactic cranial irradiation PCI starting 4 to 6 weeks after chemoradiotherapy. Throughout the study, participants are monitored for local progression-free survival and severe toxicity-free survival up to three years from the start of chemotherapy. Other assessments include overall survival, progression-free survival, tumor recurrence or metastasis, and treatment-related side effects. The study tracks these outcomes through clinical and radiological evaluations to understand the balance of effectiveness and safety between the two radiotherapy approaches.

CONDITIONS

Brief Title

Omitting CTV for Primary Tumor in LS-SCLC

Research Team

M

Ming Chen

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here